We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

42 hedge funds and large institutions have $10.3M invested in vTv Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.09% less ownership

Funds ownership: 8.31% → 7.22% (-1.1%)

13% less funds holding

Funds holding: 48 → 42 (-6)

25% less capital invested

Capital invested by funds: $13.8M → $10.3M (-$3.52M)

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

45% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 20

Holders
42
Holders Change
-6
Holders Change %
-12.5%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
11
Reduced
20
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.41M
2
Millennium Management
Millennium Management
New York
+$714K
3
HF
HRT Financial
New York
+$616K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$460K
5
Marshall Wace
Marshall Wace
United Kingdom
+$241K

Top Sellers

Rank Fund Capital Flow
1
Nuveen
Nuveen
North Carolina
-$2.1M
2
BlackRock
BlackRock
New York
-$958K
3
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$909K
4
Two Sigma Investments
Two Sigma Investments
New York
-$582K
5
State Street
State Street
Massachusetts
-$477K

VTVT Hedge Fund Activity: Q2 2021 in Review

42 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2021, worth a combined $10.3M — down 25% from $13.8M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of VTVT and 8 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 11 added.

The largest buyer was Vanguard Group, adding an estimated $2.41M. The largest seller was Nuveen, exiting entirely with an estimated $2.1M sold.

  • 42 institutional investors held vTv Therapeutics (VTVT) as of Q2 2021, down from 48 in Q1 2021.
  • Funds reported $10.3M of vTv Therapeutics stock for Q2 2021, down 25% quarter-over-quarter.
  • 8 funds opened new vTv Therapeutics positions in Q2 2021 and 14 closed out, a net change of -6 holders.
  • The largest vTv Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $2.41M added.
  • The largest vTv Therapeutics seller in Q2 2021 was Nuveen, an estimated $2.1M sold.

Based on aggregated 13F filings for Q2 2021.